efficacy and safety of bosutinib vs imatinib in indian and non indian patients with newly diagnosed chronic phase chronic myeloid leukemia subgroup analysis from the bela trial

n/

US Cosmic Visions: New Ideas in Dark Matter 2017: Community Report

This white paper summarizes the workshop "U.S. Cosmic Visions: New Ideas in Dark Matter" held at University of Maryland on March 23-25, 2017

Pazopanib versus Sunitinib in metastatic renal-cell carcinoma

BACKGROUND: Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy. METHODS: We randomly assigned 1110 patients with clear-cell, metastatic renal-cell carcinoma, in a 1:1 ratio, to receive a continuous dose of pazopanib (800 mg once daily; 557 patients) or sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment; 553 patients). The primary end point was progression-free survival as assessed by independent review, and the study was powered to show the noninferiority of pazopanib versus sunitinib. Secondary end points included overall survival, safety, and quality of life. RESULTS: Pazopanib was noninferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95% confidence interval [CI], 0.90 to 1.22), meeting the predefined noninferiority margin (upper bound of the 95% confidence interval, <1.25). Overall survival was similar (hazard ratio for death with pazopanib, 0.91; 95% CI, 0.76 to 1.08). Patients treated with sunitinib, as compared with those treated with pazopanib, had a higher incidence of fatigue (63% vs. 55%), the hand–foot syndrome (50% vs. 29%), and thrombocytopenia (78% vs. 41%); patients treated with pazopanib had a higher incidence of increased levels of alanine aminotransferase (60%, vs. 43% with sunitinib). The mean change from baseline in 11 of 14 health-related quality-of-life domains, particularly those related to fatigue or soreness in the mouth, throat, hands, or feet, during the first 6 months of treatment favored pazopanib (P<0.05 for all 11 comparisons

Observation of nuclear modifications in W-+/- boson production in pPb collisions at root s(NN)=8.16 TeV

The production of W\ub1 bosons is studied in proton-lead (pPb) collisions at a nucleon-nucleon centre-of-mass energy of 1asNN=8.16TeV. Measurements are performed in the W\ub1\u2192\u3bc\ub1\u3bd\u3bc channel using a data sample corresponding to an integrated luminosity of 173.4\ub16.1nb 121, collected by the CMS Collaboration at the LHC. The number of positively and negatively charged W bosons is determined separately in the muon pseudorapidity region in the laboratory frame |\u3b7lab\u3bc|<2.4 and transverse momentum pT\u3bc>25GeV/c. The W\ub1 boson differential cross sections, muon charge asymmetry, and the ratios of W\ub1 boson yields for the proton-going over the Pb-going beam directions are reported as a function of the muon pseudorapidity in the nucleon-nucleon centre-of-mass frame. The measurements are compared to the predictions from theoretical calculations based on parton distribution functions (PDFs) at next-to-leading-order. The results favour PDF calculations that include nuclear modifications and provide constraints on the nuclear PDF global fits